FDA warned BergaMet North America that its Cholesterol Command supplement is an unapproved new drug and misbranded because of disease claims.
What happened
In October 2022, FDA reviewed the company's website, its Facebook page, and a Walmart product listing. FDA found claims and testimonials that Cholesterol Command improves cholesterol, reduces LDL, is anti-inflammatory, and addresses diabetes, heart disease, and high blood pressure. FDA concluded the product is intended as a drug for disease treatment or prevention and is an unapproved new drug and misbranded.
What FDA found
The website, Facebook, and Walmart claims show Cholesterol Command is intended to cure, mitigate, treat, or prevent disease, which makes it a drug.
section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 321(g)(1)(B)]Cholesterol Command is a new drug because it is not generally recognized as safe and effective for its claimed uses and has no FDA approval.
section 201(p) [21 U.S.C. 321(p)]; sections 301(d) and 505(a) [21 U.S.C. 331(d), 355(a)]The product is misbranded because it lacks adequate directions for use by a layperson for diseases that need a licensed practitioner's care.
section 502(f)(1) [21 U.S.C. 352(f)(1)]; 21 CFR 201.5Selling or delivering the misbranded drug in interstate commerce violates the Act.
section 301(a) [21 U.S.C. 331(a)]
What FDA wants
Within 15 working days of receipt, FDA asks BergaMet to write to the agency with the specific steps it has taken to address the violations, an explanation of each step to prevent recurrence, and related documentation. If it cannot complete corrective action in that time, it must state why and when it will finish.
Who should pay attention
- supplement brands making cholesterol or heart-health claims
- retailers and marketplaces listing supplements with disease claims
- companies using customer testimonials in supplement marketing
This is a summary. Read the original letter on fda.gov.